UTMB Health Launches Trial to Slow Biological Aging

- The trial will specifically test tirzepatide, sold under brand names Zepbound and Mounjaro, which is a dual-action therapy targeting two hormone receptors, GLP-1 and GIP. This differs from other popular drugs like Ozempic and Wegovy that act on only one. - Researchers will use advanced biomarkers, including DNA methylation clocks, to measure if a participant's biological age changes during the 24-week treatment and if those effects persist during a 12-week follow-up period. - The study is led by Principal Investigators Dr. Thomas Blackwell, a professor of Internal Medicine and geriatrics specialist, and Dr. Alan Landay, Vice President of Team Science at UTMB. - Data points like physical performance, mood, and inflammation will be tracked, mirroring the type of health metrics consumer apps collect via wearable APIs from devices like Oura and Whoop, which specialize in recovery and physiological tracking. - The collection of such health data by consumer-facing apps falls under a complex web of privacy regulations beyond HIPAA, including the FTC's Health Breach Notification Rule and state-specific laws like Washington's My Health My Data Act, which requires explicit opt-in consent for data collection and sharing. - For consumer health startups, institutional clinical trials like this one provide a model for building trust; founders can establish credibility by investing in internal or partner research to substantiate marketing claims and publishing the results. - This trial is part of the broader scientific field of geroscience, which targets the aging process itself to prevent chronic diseases like heart disease, cancer, and dementia. - The focus on repurposing existing drugs and the rise of AI in healthcare analytics has attracted significant venture capital to the longevity space, with investors funding startups that can demonstrate tangible evidence of market traction and clinical outcomes.